Argos Therapeutics Inc. (NASDAQ:ARGS) saw strong trading volume on Friday after an insider bought additional shares in the company. 175,394 shares changed hands during mid-day trading, an increase of 10% from the previous session’s volume of 158,770 shares.The stock last traded at $4.63 and had previously closed at $4.52.

Specifically, major shareholder International S. Pharmstandard purchased 5,580 shares of Argos Therapeutics stock in a transaction dated Monday, September 19th. The stock was purchased at an average cost of $4.76 per share, with a total value of $26,560.80. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder International S. Pharmstandard purchased 75,474 shares of Argos Therapeutics stock in a transaction dated Monday, August 22nd. The stock was bought at an average cost of $4.24 per share, with a total value of $320,009.76. The disclosure for this purchase can be found here. 61.64% of the stock is owned by company insiders.

Several research analysts have recently commented on the company. Zacks Investment Research lowered Argos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Argos Therapeutics in a research report on Friday, June 17th. FBR & Co reduced their price target on Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 11th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $11.00 price target on shares of Argos Therapeutics in a research report on Monday, June 20th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $11.50.

The stock’s market cap is $189.91 million. The firm’s 50 day moving average is $4.89 and its 200-day moving average is $5.90.

Argos Therapeutics (NASDAQ:ARGS) last released its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.05. Analysts forecast that Argos Therapeutics Inc. will post ($1.56) earnings per share for the current year.

Hedge funds have recently bought and sold shares of the stock. BlackRock Fund Advisors boosted its stake in Argos Therapeutics by 880.1% in the second quarter. BlackRock Fund Advisors now owns 281,679 shares of the biopharmaceutical company’s stock worth $1,727,000 after buying an additional 252,940 shares in the last quarter. Vanguard Group Inc. boosted its stake in Argos Therapeutics by 57.2% in the second quarter. Vanguard Group Inc. now owns 377,497 shares of the biopharmaceutical company’s stock worth $2,314,000 after buying an additional 137,390 shares in the last quarter. State Street Corp acquired a new stake in Argos Therapeutics during the second quarter worth $741,000. BlackRock Institutional Trust Company N.A. acquired a new stake in Argos Therapeutics during the second quarter worth $363,000. Finally, Oxford Asset Management acquired a new stake in Argos Therapeutics during the second quarter worth $353,000. Institutional investors own 11.05% of the company’s stock.

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

5 Day Chart for NASDAQ:ARGS

Receive News & Stock Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related stocks with our FREE daily email newsletter.